In vivo studies using two murine models of T1D—RIP-LCMV-GP mice and NOD mice—demonstrated that TYK2 inhibition via deucravacitinib administration attenuated systemic and tissue-localized inflammation, preserved beta cell viability, and delayed autoimmune diabetes onset. The gene discussed is TYK2; the disease is type 1 diabetes mellitus.